Cytek Biosciences, Inc.
CTKB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $847,665 | $1,233,781 | $1,373,356 | $2,182,795 |
| - Cash | $98,716 | $167,299 | $296,601 | $364,618 |
| + Debt | $17,016 | $14,136 | $18,094 | $0 |
| Enterprise Value | $765,965 | $1,080,618 | $1,094,849 | $1,818,177 |
| Revenue | $200,453 | $193,015 | $164,036 | $127,950 |
| % Growth | 3.9% | 17.7% | 28.2% | – |
| Gross Profit | $111,106 | $109,426 | $100,974 | $79,144 |
| % Margin | 55.4% | 56.7% | 61.6% | 61.9% |
| EBITDA | -$10,033 | -$4,408 | $9,492 | $8,921 |
| % Margin | -5% | -2.3% | 5.8% | 7% |
| Net Income | -$6,020 | -$12,148 | $2,576 | $3,001 |
| % Margin | -3% | -6.3% | 1.6% | 2.3% |
| EPS Diluted | -0.046 | -0.09 | 0.019 | 0.033 |
| % Growth | 48.7% | -582.8% | -43.6% | – |
| Operating Cash Flow | $25,379 | $5,281 | -$12,231 | $4,630 |
| Capital Expenditures | -$3,525 | -$4,827 | -$9,868 | -$4,364 |
| Free Cash Flow | $21,854 | $454 | -$22,099 | $266 |